ATE459360T1 - Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen - Google Patents

Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen

Info

Publication number
ATE459360T1
ATE459360T1 AT03768074T AT03768074T ATE459360T1 AT E459360 T1 ATE459360 T1 AT E459360T1 AT 03768074 T AT03768074 T AT 03768074T AT 03768074 T AT03768074 T AT 03768074T AT E459360 T1 ATE459360 T1 AT E459360T1
Authority
AT
Austria
Prior art keywords
subject
regulating
immune response
phosphoantigen
compositions containing
Prior art date
Application number
AT03768074T
Other languages
English (en)
Inventor
Francois Romagne
Helene Sicard
Jerome Tiollier
Christian Belmant
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE459360T1 publication Critical patent/ATE459360T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT03768074T 2002-12-02 2003-12-02 Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen ATE459360T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292963A EP1426052B1 (de) 2002-12-02 2002-12-02 Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
PCT/IB2003/006375 WO2004050096A2 (en) 2002-12-02 2003-12-02 Phosphoantigens for regulating an immune response

Publications (1)

Publication Number Publication Date
ATE459360T1 true ATE459360T1 (de) 2010-03-15

Family

ID=32309486

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02292963T ATE441420T1 (de) 2002-12-02 2002-12-02 Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
AT03768074T ATE459360T1 (de) 2002-12-02 2003-12-02 Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02292963T ATE441420T1 (de) 2002-12-02 2002-12-02 Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen

Country Status (8)

Country Link
US (2) US20060194755A1 (de)
EP (2) EP1426052B1 (de)
JP (1) JP2006510629A (de)
AT (2) ATE441420T1 (de)
AU (1) AU2003292492B2 (de)
CA (1) CA2507011A1 (de)
DE (2) DE60233576D1 (de)
WO (1) WO2004050096A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
US20100291118A1 (en) * 2003-12-02 2010-11-18 Innate Pharma Class of Gamma Delta T Cells Activators and Use Thereof
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen
ATE419008T1 (de) 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
DE602005022728D1 (de) * 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US7687482B2 (en) 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CA2602223A1 (en) 2005-03-22 2006-10-05 Christian Belmant New class of yo t cells activators and use thereof
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
WO2008124756A1 (en) * 2007-04-09 2008-10-16 The Regents Of The University Of Colorado Compositions and methods for treating bone cancer
EP2150258A2 (de) * 2007-06-01 2010-02-10 Innate Pharma S.A. Verbessertes verfahren zur verwendung von phosphoantigenen in verbindung mit interleukin-2 zur krebsbehandlung
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
EP2123285A1 (de) 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosid-Phosphorantigene zur Verwendung in der VGAMMA9VDELTA2-T-Zellen-vermittelten Therapie
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
BR112013023151A2 (pt) * 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
DK2683395T3 (en) * 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
JP2016501013A (ja) * 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
EP3041494A4 (de) * 2013-09-05 2017-10-18 Sanford-Burnham Medical Research Institute Modulation von gamma delta t-zellen
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896871B2 (en) * 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
JP2002519007A (ja) * 1998-06-30 2002-07-02 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド ヒトγ−δＴ細胞機能の特異的モジュレータとしてのアルキルアミンおよびそれらの前駆体
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
EP1153928B1 (de) * 1999-01-21 2005-12-21 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
US20050042751A1 (en) * 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
FR2836483B1 (fr) * 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
EP1720567A2 (de) * 2004-02-10 2006-11-15 Innate Pharma Zusammensetzung und verfahren zur behandlung von karzinomen

Also Published As

Publication number Publication date
WO2004050096A2 (en) 2004-06-17
DE60331583D1 (de) 2010-04-15
DE60233576D1 (de) 2009-10-15
EP1426052A1 (de) 2004-06-09
JP2006510629A (ja) 2006-03-30
EP1569656A2 (de) 2005-09-07
ATE441420T1 (de) 2009-09-15
CA2507011A1 (en) 2004-06-17
AU2003292492B2 (en) 2008-10-23
US20060194755A1 (en) 2006-08-31
EP1426052B1 (de) 2009-09-02
AU2003292492A1 (en) 2004-06-23
US20100254940A1 (en) 2010-10-07
EP1569656B1 (de) 2010-03-03
WO2004050096A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE459360T1 (de) Phosphoantigen enthaltene zusammensetzungen zur regulierung von immunereaktionen
SG151278A1 (en) Oral and personal care compositions and methods
MY155909A (en) Oral care compositions and methods
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
IL172700A (en) Methods for making neutralizing and cross-activating antibodies against kir2dl and drugs that include them for use in assessing antibody toxicity
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DE60315847D1 (de) Varianten des menschliche koagulationsfaktors vii
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
ATE446313T1 (de) Muteine von tränen-lipocalin
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
PL1669367T3 (pl) Peptydy, które mogą wiązać się z transformującym czynnikiem wzrostu beta 1 (TGF-BETA1)
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
DK0631772T3 (da) Retinoidholdig sammensætning
ATE333451T1 (de) Verwendung von nitrilenverbindungen als arztneimittel
TW200501993A (en) Oral care compositions and methods
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
MXPA05013226A (es) Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas.
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
YU38103A (sh) Nova jedinjenja askorbinske kiseline, postupci sinteze i način njihove primene
IL174594A (en) MANIPULATED NKT CELLS MODULATING THE Th1/Th2 BALANCE, USES AND THERAPEUTIC COMPOSITIONS THEREOF IN THE TREATMENT OF IMMUNE-RELATED DISORDERS
ATE225183T1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties